- Home
- FGEN vs KLRS Comparison
FGEN vs KLRS Comparison
Compare FGEN & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FGEN
- KLRS
- Stock Information
- Founded
- FGEN 1993
- KLRS 2019
- Country
- FGEN United States
- KLRS United States
- Employees
- FGEN N/A
- KLRS N/A
- Industry
- FGEN Biotechnology: Pharmaceutical Preparations
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FGEN Health Care
- KLRS Health Care
- Exchange
- FGEN Nasdaq
- KLRS Nasdaq
- Market Cap
- FGEN 38.4M
- KLRS 46.0M
- IPO Year
- FGEN 2014
- KLRS N/A
- Fundamental
- Price
- FGEN $10.56
- KLRS $2.57
- Analyst Decision
- FGEN Strong Buy
- KLRS Buy
- Analyst Count
- FGEN 2
- KLRS 1
- Target Price
- FGEN $146.50
- KLRS N/A
- AVG Volume (30 Days)
- FGEN 66.4K
- KLRS 59.8K
- Earning Date
- FGEN 08-11-2025
- KLRS 08-13-2025
- Dividend Yield
- FGEN N/A
- KLRS N/A
- EPS Growth
- FGEN N/A
- KLRS N/A
- EPS
- FGEN N/A
- KLRS N/A
- Revenue
- FGEN $7,346,000.00
- KLRS N/A
- Revenue This Year
- FGEN N/A
- KLRS N/A
- Revenue Next Year
- FGEN N/A
- KLRS N/A
- P/E Ratio
- FGEN N/A
- KLRS N/A
- Revenue Growth
- FGEN N/A
- KLRS N/A
- 52 Week Low
- FGEN $4.50
- KLRS $2.14
- 52 Week High
- FGEN $21.94
- KLRS $24.15
- Technical
- Relative Strength Index (RSI)
- FGEN 68.96
- KLRS N/A
- Support Level
- FGEN $9.05
- KLRS N/A
- Resistance Level
- FGEN $11.71
- KLRS N/A
- Average True Range (ATR)
- FGEN 0.77
- KLRS 0.00
- MACD
- FGEN 0.32
- KLRS 0.00
- Stochastic Oscillator
- FGEN 76.95
- KLRS 0.00
About FGEN FibroGen Inc
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.